Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
주식 순위 #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
주가
$64.97
마지막 동기화: 2024-05-20
시가총액
$1.97B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Alpine Immune Sciences, Inc. (ALPN)

카테고리

Alpine Immune Sciences, Inc. (ALPN)의 EPS
March 2024 기준 EPS TTM: $-0.69
Alpine Immune Sciences, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.69입니다. 2022년 말에는 회사의 EPS가 $-1.73였으며, 이는 2021년의 EPS $-1.98와 감소입니다.
Alpine Immune Sciences, Inc.의 EPS 기록 (2012 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-0.69 7.81%
2023 $-0.64 -63.01%
2022 $-1.73 -12.63%
2021 $-1.98 47.76%
2020 $-1.34 -42.24%
2019 $-2.32 -11.79%
2018 $-2.63 119.17%
2017 $-1.20 -85.22%
2016 $-8.12 -16.63%
2015 $-9.74 47.80%
2014 $-6.59 -7.18%
2013 $-7.10 69.05%
2012 $-4.20 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -2,610.14%
US
$27.74 -4,120.29%
NL
$-5.29 666.67%
AU
$-7.98 1,056.52%
US
- -
CH